Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation

被引：0
|
作者：
Cho, B. C. [1 ]
Shen, Y. [2 ]
Li, Z. [3 ]
Lu, S. [3 ]
Lee, M. A. [4 ]
Song, Z. [5 ]
Park, J. J. W. [6 ]
Lim, S. M. [1 ]
Zhao, J. [7 ]
Richardson, G. [8 ]
Zhang, Y. [9 ]
Zhang, J. [2 ,10 ]
Liu, A. [11 ]
Chen, C. [2 ]
Liu, Y. [2 ]
Rui, H. [2 ]
Chen, J. Q. [2 ]
Wang, A. H. [2 ]
Zhang, J. [2 ,10 ]
Mok, T. S. K. [12 ]
机构：
[1] Yonsei Univ, ABMRC, Med Oncol Dept 501, Seoul, South Korea
[2] D3 Bio Wuxi Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[4] Catholic Univ Korea, Seoul St Marys Hosp, Internal Med Dept, Catholic Med Ctr, Seoul, South Korea
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Clin Trials Dept, Hangzhou, Peoples R China
[6] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept Level 1, Sydney, NSW, Australia
[7] Beijing Canc Hosp, Dept Oncol, Beijing, Peoples R China
[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Szalmuk Family Dept Med Oncol, Malvern, Vic, Australia
[9] Harbin Med Univ, Canc Hosp, Gastroenterol Dept, Harbin, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Oncol Dept, Shanghai, Peoples R China
[11] Nanchang Univ, Affiliated Hosp 2, Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Prince Wales Hosp, Clin Oncol Dept, Li Ka Shing Specialist Clin, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
640P
引用
收藏
页码：S1642 / S1643
页数：2
相关论文
共 50 条
  • [21] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [22] Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
    Idowu, O.
    Craigen, J.
    Svetlik, S.
    Veal, J.
    Jamieson, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
  • [23] A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
    Spira, A.
    Riely, G.
    Lawler, W.
    Shum, M.
    Socinski, M.
    Yanagihara, R.
    Roshan, S.
    Kheoh, T.
    Christensen, J.
    Chao, R.
    Janne, P.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S696
  • [24] A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
    Mateo, Joaquin
    De Bono, Johann Sebastian
    Ramanathan, Ramesh K.
    Lustberg, Maryam B.
    Zivi, Andrea
    Basset, Dawn
    Ng, Matthew
    Young, Anna-Mary
    Garrett, Michelle
    Decordova, Shaun
    Raynaud, Florence I.
    Yap, Timothy Anthony
    Zukiwski, Alexander A.
    Proniuk, Stefan
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
    Solomon, Benjamin
    Heist, Rebecca S.
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Dooms, Christophe
    Van Cutsem, Eric
    Steuer, Conor E.
    Steeghs, Neeltje
    Schuler, Martin
    Gazzah, Anas
    Wermke, Martin
    Felip, Enriqueta
    Loong, Herbert H. F.
    Luken, Maria J. De Miguel
    Soo, Ross A.
    Jaeger, Ashley
    Xu, Kun
    Chen, Xueying
    Cui, Xiaoming
    Burks, Heather
    Farago, Anna F.
    Shimizu, Toshio
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [26] AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial
    Strickler, J. H.
    Fakih, M.
    Price, T. J.
    Desai, J.
    Durm, G.
    Krauss, J. C.
    Kuboki, Y.
    Kim, T. W.
    Sacher, A.
    Henary, H.
    Kim, J.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1274 - S1275
  • [27] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
  • [28] Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in solid tumors with KRAS G12C mutation: Results from a phase Ib/II study
    Song, Z.
    Li, X.
    Liu, Y.
    Yuan, Y.
    Lin, R.
    Shi, H.
    Luo, Y.
    Lv, T.
    Zhang, Y.
    Zhu, L.
    Zhu, Y.
    Xie, S.
    Zhang, B.
    Wang, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S497 - S498
  • [29] AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial
    Strickler, J.
    Fakih, M.
    Price, T.
    Desai, J.
    Durm, G.
    Krauss, J.
    Kuboki, Y.
    Kim, T.
    Sacher, A.
    Henary, H.
    Kim, J.
    Hong, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S226 - S226
  • [30] Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
    Nagase, Mario
    Houk, Brett
    Vuu, Irene
    Cardona, Panli
    Dutta, Sandeep
    Lin, Chih-Wei
    AAPS JOURNAL, 2025, 27 (01):
12345